渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

已收盘 03-28 16:00:00 EDT

138.37

-1.96

-1.40%

盘后138.13

-0.24-0.17%

19:49 EDT

最高141.25	最低138.20	成交量109.40万
今开140.60	昨收140.33	日振幅2.17%
总市值202.54亿	流通市值202.03亿	总股本1.46亿
成交额1.52亿	换手率0.75%	流通股本1.46亿
市净率1.21	ROE10.36%	每股收益11.18
52周最高238.00	52周最低128.51	市盈率12.38
股息0.00	股息收益率0.00	ROA5.29%

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":138.37,"timestamp":1743192000000,"preClose":140.33,"halted":0,"volume":1094040,"hourTrading":{"tag":"盘后","latestPrice":138.13,"preClose":138.37,"latestTime":"19:49 EDT","volume":59607,"amount":8247827.0915,"timestamp":1743205782742},"delay":0,"floatShares":146004081,"shares":146374937,"eps":11.18,"marketStatus":"已收盘","change":-1.96,"latestTime":"03-28 16:00:00 EDT","open":140.6,"high":141.245,"low":138.2,"amount":152149488.46920002,"amplitude":0.021699,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":11.18,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":685080000000,"exchange":"NASDAQ","adjPreClose":140.33,"preHourTrading":{"tag":"盘前","latestPrice":139.6908,"preClose":140.33,"latestTime":"09:05 EDT","volume":278,"amount":39002.33248,"timestamp":1743167152003},"postHourTrading":{"tag":"盘后","latestPrice":138.13,"preClose":138.37,"latestTime":"19:49 EDT","volume":59607,"amount":8247827.0915,"timestamp":1743205782742},"volumeRatio":0.550725,"impliedVol":0.422,"impliedVolPercentile":0.912},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"2511670793","title":"渤健公司2024财年实现净利润16.32亿美元，同比增加40.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511670793","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511670793?lang=zh_cn&edition=full","pubTime":"2025-02-16 00:01","pubTimestamp":1739635291,"startTime":"0","endTime":"0","summary":"2月16日，渤健公司公布财报，公告显示公司2024财年净利润为16.32亿美元，同比增加40.57%；其中营业收入为96.76亿美元，同比增加2.75%，每股基本收益为11.21美元。从资产负债表来看，渤健公司总负债113.33亿美元，其中短期债务17.49亿美元，资产负债比为2.48，流动比率为1.35。机构评级：截至2025年2月16日，当前有28家机构对渤健公司目标价做出预测，其中目标均价为194.61美元，其中最低目标价为135.00美元，最高目标价为342.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000157a24729f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000157a24729f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIIB"],"gpt_icon":1},{"id":"2511573403","title":"加拿大蒙特利尔银行：维持Biogen(BIIB.US)评级，由大市一致调整至大市一致评级, 目标价由156.00美元调整至139.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511573403","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511573403?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:55","pubTimestamp":1739469300,"startTime":"0","endTime":"0","summary":"加拿大蒙特利尔银行：维持Biogen(BIIB.US)评级，由大市一致调整至大市一致评级, 目标价由156.00美元调整至139.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/14015548150658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BMO","BIIB"],"gpt_icon":0},{"id":"2511734125","title":"大摩：维持Biogen(BIIB.US)评级，由持股观望调整至持股观望评级, 目标价由192.00美元调整至157.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511734125","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511734125?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:48","pubTimestamp":1739468882,"startTime":"0","endTime":"0","summary":"大摩：维持Biogen(BIIB.US)评级，由持股观望调整至持股观望评级, 目标价由192.00美元调整至157.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/14014848150637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BIIB"],"gpt_icon":0},{"id":"2511520680","title":"加拿大皇家银行：维持Biogen(BIIB.US)评级，由优于大市调整至优于大市评级, 目标价由231.00美元调整至225.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511520680","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511520680?lang=zh_cn&edition=full","pubTime":"2025-02-14 00:52","pubTimestamp":1739465543,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持Biogen(BIIB.US)评级，由优于大市调整至优于大市评级, 目标价由231.00美元调整至225.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/14005248150528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BIIB"],"gpt_icon":0},{"id":"2511527781","title":"花旗：维持Biogen(BIIB.US)评级，由中性调整至中性评级, 目标价由160.00美元调整至145.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511527781","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511527781?lang=zh_cn&edition=full","pubTime":"2025-02-14 00:45","pubTimestamp":1739465131,"startTime":"0","endTime":"0","summary":"花旗：维持Biogen(BIIB.US)评级，由中性调整至中性评级, 目标价由160.00美元调整至145.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/14004548150496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BIIB"],"gpt_icon":0},{"id":"2511521948","title":"富国银行：维持Biogen(BIIB.US)评级，由持股观望调整至持股观望评级, 目标价由165.00美元调整至140.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511521948","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511521948?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:25","pubTimestamp":1739460304,"startTime":"0","endTime":"0","summary":"富国银行：维持Biogen(BIIB.US)评级，由持股观望调整至持股观望评级, 目标价由165.00美元调整至140.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13232548149600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BIIB"],"gpt_icon":0},{"id":"2511523324","title":"HC Wainwright & Co.：维持Biogen(BIIB.US)评级，由买入调整至买入评级, 目标价由300.00美元调整至241.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511523324","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511523324?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:04","pubTimestamp":1739455445,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Biogen(BIIB.US)评级，由买入调整至买入评级, 目标价由300.00美元调整至241.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13220448149021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BIIB"],"gpt_icon":0},{"id":"2511581323","title":"Biogen：砍掉4条管线，并达成18亿元的交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2511581323","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511581323?lang=zh_cn&edition=full","pubTime":"2025-02-13 00:01","pubTimestamp":1739376084,"startTime":"0","endTime":"0","summary":"2月12日，渤健发布了2024年财报，总营收97亿美元，同比下降2%，GAAP稀释每股收益11.18美元，同比增长40%；Non-GAAP稀释了每股收益16.47美元，同比增长12%；研发投入20.42亿美元，现金和现金等价物27亿美元。渤健/卫材的仑卡奈单抗是20年来首款被FDA完全批准的AD治疗药物，被列入Science2023年度十大科学突破。同时，根据财报，渤健与Royalty Pharma就一种名为litfilimab的抗BDCA2药物达成协议，该药物目前正处于治疗两种狼疮的三期试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213033924abcc9e7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213033924abcc9e7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2271345857.HKD","LU0234570918.USD","BK4581","LU1363072403.SGD","BK4504","LU0795875169.SGD","LU2089283258.USD","LU0106261372.USD","LU0320765646.SGD","IE00BKVL7J92.USD","LU2023251221.USD","LU0267386448.USD","BIIB","LU1162221912.USD","LU1548497426.USD","LU1668664300.SGD","LU0225283273.USD","LU0106831901.USD","LU0889565916.HKD","BK4532","IE00BZ1G4Q59.USD","LU0314104364.USD","LU2133065610.SGD","BK4534","LU1989772923.USD","LU0320765992.SGD","LU2111349929.HKD","IE00B19Z9Z06.USD","LU2028103732.USD","LU2089284900.SGD","LU1732800096.USD","IE00B894F039.SGD","LU0109394709.USD","BK4533","BK4585","LU0006306889.USD","LU0158827948.USD","BK4588","BK4516","LU2347655156.SGD","LU2357305700.SGD","BK4127","LU0971096721.USD","LU0158827781.USD","LU1989772840.SGD","LU1732799900.SGD","LU0098860793.USD","LU0795875086.SGD","LU1720051017.SGD","BK4139"],"gpt_icon":1},{"id":"1199181976","title":"异动解读 | 渤健公司(BIIB)盘中大跌6.54% 成本增加、销售放缓及美元走强拖累利润展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1199181976","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199181976?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:43","pubTimestamp":1739371405,"startTime":"0","endTime":"0","summary":"渤健公司今日(周三)盘中大跌6.54%,引发市场广泛关注。导致公司股价大跌的主要原因是该公司公布了疲软的2025年利润预期,低于华尔街分析师预期。据消息,渤健公司预计2025年在剔除汇率影响后,收入将比2024年水平下降中等个位数百分比。虽然渤健公司去年聘请了前赛诺菲CEO担任首席执行官,并启动10亿美元成本削减计划、收购Reata制药公司等措施,但似乎难以完全抵消上述不利影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIIB"],"gpt_icon":0},{"id":"2510308407","title":"渤健公司盘中异动 早盘股价大跌5.79%报131.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510308407","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510308407?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:33","pubTimestamp":1739370797,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日22时33分，渤健公司股票出现波动，股价急速下跌5.79%。截至发稿，该股报131.32美元/股，成交量20.1474万股，换手率0.14%，振幅3.73%。渤健公司股票所在的制药行业中，整体跌幅为0.19%。消息层面，截至22时33分，《新药Leqembi热销助业绩超预期 难掩百健未来利润增长压力》资讯为影响渤健公司的重要信息。截至12月31日的第四季度，排除某些项目后，百健每股收益为3.44美元，同比增长17%，高于分析师预期的3.35美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212223317a243549c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212223317a243549c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B894F039.SGD","LU0889565916.HKD","IE00B19Z9P08.USD","BK4139","BK4585","LU0320765992.SGD","LU0234570918.USD","IE00B19Z9Z06.USD","BK4588","BK4532","BIIB","BK4533","LU0109394709.USD"],"gpt_icon":0},{"id":"2510244376","title":"新药Leqembi热销助业绩超预期 难掩百健(BIIB.US)未来利润增长压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2510244376","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510244376?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:52","pubTimestamp":1739364723,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百健公布了营收和利润超预期的第四季度业绩，显示出其成本削减措施取得进展，以及包括突破性阿尔茨海默病治疗药物Leqembi在内的新产品实现了增长。其中，Leqembi创造了约8700万美元的营收，超出市场预期。Viehbacher致力于推动Leqembi销售增长、削减成本并减少公司对高风险神经科学治疗的依赖。与此同时，百健多发性硬化症治疗药物的销售额下降了8%，至10.7亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1249077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B19Z9P08.USD","BK4585","IE00B19Z9Z06.USD","BK4532","LU0320765992.SGD","BIIB","BK4533","LU0109394709.USD","BK4139","LU0234570918.USD","BK4588","LU0889565916.HKD","IE00B894F039.SGD"],"gpt_icon":0},{"id":"2510391378","title":"百健(BIIB.O)：预计毛利率和营业利润率同比保持相对平稳。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510391378","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510391378?lang=zh_cn&edition=full","pubTime":"2025-02-12 19:58","pubTimestamp":1739361536,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4533","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BK4532","LU0320765992.SGD","BK4588","BK4139","BIIB","LU0234570918.USD","LU0109394709.USD","LU0889565916.HKD","IE00B894F039.SGD","BK4585"],"gpt_icon":0},{"id":"1104002176","title":"Biogen 2024年第四季度调整后每股收益为$3.44，超出预期的$3.35；销售额为$24.6亿，超出预期的$24亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1104002176","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104002176?lang=zh_cn&edition=full","pubTime":"2025-02-12 19:58","pubTimestamp":1739361491,"startTime":"0","endTime":"0","summary":"Biogen报告其季度每股收益为$3.44，这一数字比分析师一致预期的$3.35高出2.69%。较去年同期销售额$23.9亿增长了2.89%。以上内容来自Benzinga Earnings专栏，原文如下：Biogen  reported quarterly earnings of $3.44 per share which beat the analyst consensus estimate of $3.35 by 2.69 percent. This is a 16.61 percent increase over earnings of $2.95 per share from the same period last year.  The company reported quarterly sales of $2.46 billion which beat the analyst consensus estimate of $2.40 billion by 2.17 percent.  This is a 2.89 percent increase over sales of","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Biogen 2024年第四季度调整后每股收益为$3.44，超出预期的$3.35；销售额为$24.6亿，超出预期的$24亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"gpt_icon":1},{"id":"1197288804","title":"异动解读 | 渤健公司盘前大跌5.3% 预测2025年利润低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1197288804","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197288804?lang=zh_cn&edition=full","pubTime":"2025-02-12 19:52","pubTimestamp":1739361156,"startTime":"0","endTime":"0","summary":"渤健公司(BIIB)今日盘前大跌5.3%,引发市场广泛关注。这一下跌或与公司此前发布的2025年利润预测低于预期有关。\n\n消息显示,渤健公司预计2025年如果剔除汇率影响,收入将比2024年下降一个中个位数。公司预计2025年每股收益将在15.25美元至16.25美元之间,低于分析师此前的预期。\n\n导致利润预测下滑的主要原因包括:美元走强、阿尔茨海默病新药销售放缓、成本上升等。渤健公司在2022年雇佣了前赛诺菲公司CEO担任总裁,启动10亿美元成本削减计划,并在去年斥资65亿美元收购Reata制药公司。但上述措施似乎还无法完全抵消各种不利因素的影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 渤健公司盘前大跌5.3% 预测2025年利润低于预期","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIIB"],"gpt_icon":0},{"id":"2506594518","title":"花旗：维持Biogen(BIIB.US)评级，由中性调整至中性评级, 目标价由190.00美元调整至160.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506594518","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506594518?lang=zh_cn&edition=full","pubTime":"2025-01-28 20:34","pubTimestamp":1738067694,"startTime":"0","endTime":"0","summary":"花旗：维持Biogen(BIIB.US)评级，由中性调整至中性评级, 目标价由190.00美元调整至160.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/28203447881834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BIIB"],"gpt_icon":0},{"id":"2506372292","title":"卫材“仑卡奈单抗“获FDA批准治疗早期阿尔茨海默病","url":"https://stock-news.laohu8.com/highlight/detail?id=2506372292","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506372292?lang=zh_cn&edition=full","pubTime":"2025-01-27 20:48","pubTimestamp":1737982103,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月26日，卫材和渤健共同宣布仑卡奈单抗静脉注射制剂的补充生物制品许可申请获得FDA批准，用于每4周1次维持治疗早期阿尔茨海默病患者，即存在轻度认知障碍或处于轻度痴呆阶段的AD患者。AD是一种持续的神经毒性过程，在Aβ斑块沉积之前开始并在Aβ斑块沉积之后持续进展。治疗早期AD是当务之急，因为在早期进行持续治疗可以减缓AD的进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012720520498749cf4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012720520498749cf4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIIB","LU0320765992.SGD","BK4585","IE00B19Z9P08.USD","BK4139","BK4588","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","BK4533","IE00B894F039.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2506371692","title":"卫材(ESALY.US)/渤健(BIIB.US)“仑卡奈单抗“获FDA批准治疗早期阿尔茨海默病","url":"https://stock-news.laohu8.com/highlight/detail?id=2506371692","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506371692?lang=zh_cn&edition=full","pubTime":"2025-01-27 20:48","pubTimestamp":1737982103,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月26日，卫材和渤健共同宣布仑卡奈单抗静脉注射制剂的补充生物制品许可申请获得FDA批准，用于每4周1次维持治疗早期阿尔茨海默病患者，即存在轻度认知障碍或处于轻度痴呆阶段的AD患者。AD是一种持续的神经毒性过程，在Aβ斑块沉积之前开始并在Aβ斑块沉积之后持续进展。治疗早期AD是当务之急，因为在早期进行持续治疗可以减缓AD的进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1244773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"卫材(ESALY.US)/渤健(BIIB.US)“仑卡奈单抗“获FDA批准治疗早期阿尔茨海默病","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","IE00B19Z9P08.USD","LU0889565916.HKD","BK4588","BIIB","IE00B894F039.SGD","LU0320765992.SGD","BK4533","IE00B19Z9Z06.USD","LU0234570918.USD","BK4585","BK4532","BK4139"],"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启，投资机会如何掘金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启，有哪些投资机会可以布局？值得一提的是，科技股在特朗普任期内表现尤为突出，成为推动美股上涨的主要力量。在特朗普第一个任期内，美元整体表现相对弱势。4年任期内，美元指数累计下跌了10.53%。而纵观全球市场，在特朗普上一任期内，恒生科技指数涨幅超过147%，表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DLTR","CASY","PODD","CINF","LIN","LSCC","OKTA","COIN","LPLA","PAYX","SBAC","ROST","BSY","NTES","META","TRMB","CHDN","KDP","NXPI","SFM","AMZN","BK4086","JKHY","LAMR","INTC","AMGN","MPWR","TSLA","TPG","CYBR","HLNE","SQQQ","NTNX","NVIW.SI","PCVX","GMAB","CCEP","FRPT","TSYW.SI","NBIX","MNDY","DOCU","PTC","ENTG","SOFI","ITCI","CTAS","SBUX","BPMC","GRAB","DPZ","KHC","CG","FWONK","HOLX","PARA","DASH","INSM","ISRG","QCOM","ESLT","ROP","ILMN","SSNC","ADSK","SWKS","ORLY","TXN","LKQ","AVGO","ROKU","LECO","BMRN","SRPT","RKLB","TSCO","POOL","TEAM","PEP","EA","NTRA","JBHT","LSTR","MELI","BK4585","MDB","QLD","REGN","DDOG","NTAP","AAPL","AUR","GOOGL","BKNG","PDD","EXE","HOOD","LI","EXAS","NDSN","HSIC","NFLX","TER","FOX","LU2065731478.USD","WYNN","HQY","AMAT","AZN","LNW","CME","CPRT","MTSI","REG","CHKP","CSWI","RIVN","ANSS","HTHT","AEP","OLED","ARGX","CDNS","MKSI","ON","LU0757428866.USD","MANH","HON","RGEN","HBAN","TCOM","ALGN","TMUS","ASML","AFRM","CPB","DOX","FSLR","ICLR","TECH","CHRW","CSX","DKNG","NDAQ","CSGP","EBAY","NQmain","FSV","LU1815336091.USD","FTNT","ADI","TTEK","MNST","NVDA","ARM","EQIX","MTCH","NVMI","CRWD","AAL","ODFL","ONC","MEDP","SEIC","AKAM","GILD","CEG","QID","FFIV","TLN","PAA","TTWO","ROIV","BRKR","JD","CSCO","WBA","MIDD","CHTR","AAON","COKE","SNPS","PNFP","CHRD","ADBE","BK4561","FER","PLTR","EVRG","IDXX","ERIC","GTLB","AMD","OTEX","NTRS","FAST","CZR","QQQ","BK4581","EXPE","FOXA","FTAI","ULTA","WWD","COST","MARA","MRNA","TROW","BK4588","TSEM","BK4550","PSQ","MRVL","WTFC","APA","MKTX","Z","CBSH","LU0053671581.USD","FYBR","RADX","HST","BPOP","PCTY","BKR","MCHP","TTD","STX","USJW.SI","ALNY","TQQQ","ALAB","COO","DSGX","ZS","TW","MDLZ",".IXIC","SMCI","ENPH","MSFT","ZM","EWBC","PFG","PCAR","FCNCA","USAW.SI","BIIB","MMYT","RGLD","WDC","ERIE","GEN","LOGI","GNTX","STLD","NWSA","QXO","CDW","LNT","CTSH","GEHC","RPRX","RYAAY","SIRI","AXON","CFLT","GLPI","QRVO","CWST","BK4534","BK4593","MNQmain","NICE","SAIA","INTU","RVMD","DUOL","INCY","AGNC","LULU"],"gpt_icon":1},{"id":"2503865376","title":"渤健公司盘中异动 下午盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503865376","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503865376?lang=zh_cn&edition=full","pubTime":"2025-01-15 04:04","pubTimestamp":1736885051,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日04时04分，渤健公司股票出现波动，股价急速下挫5.01%。截至发稿，该股报142.66美元/股，成交量95.4903万股，换手率0.66%，振幅4.97%。机构评级方面，在所有36家参与评级的机构中，56%的券商给予买入建议，44%的券商给予持有建议，无券商给予卖出建议。渤健公司股票所在的制药行业中，整体跌幅为3.90%。渤健公司公司简介：Biogen和Idec于2003年合并，联手销售Biogen的多发性硬化症药物Avonex和Idec的癌症药物Rituxan。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501150404119603b4bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501150404119603b4bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","BK4532","BK4588","IE00B19Z9Z06.USD","IE00B894F039.SGD","BIIB","BK4533","LU0109394709.USD","LU0320765992.SGD","BK4139","BK4585","LU0234570918.USD","IE00B19Z9P08.USD"],"gpt_icon":1},{"id":"2502271808","title":"百健拟溢价30%收购Sage剩余股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2502271808","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502271808?lang=zh_cn&edition=full","pubTime":"2025-01-11 13:54","pubTimestamp":1736574891,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国制药商百健周五宣布，将以每股7.22美元的价格收购其尚未持有的Sage Therapeutics流通股，推动后者股价在美股盘后交易中上涨34%。监管文件显示，百健拥有Sage Therapeutics 10.2%的股份。此次报价较Sage Therapeutics周五收盘价有30%的溢价，对Sage的估值为4.417亿美元。由于对成本、疗效和副作用的担忧，百健的阿尔茨海默病药物Leqembi在美国的销售一直在缓慢回升。Sage股价在2024年暴跌75%。去年7月，Sage还放弃了与百健合作开发的另一种神经系统疾病药物。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236418.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"百健拟溢价30%收购Sage剩余股份","news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIIB","LU0320765992.SGD","BK4585","IE00B19Z9P08.USD","BK4139","BK4588","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","BK4533","SAGE","IE00B894F039.SGD","LU0109394709.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com","stockEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0218},{"period":"3month","weight":-0.0726},{"period":"6month","weight":-0.2791},{"period":"1year","weight":-0.3513},{"period":"ytd","weight":-0.0823}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学；阿尔茨海默病（AD）和痴呆症；神经肌肉疾病，包括脊髓肌萎缩症（SMA）和肌萎缩侧索硬化症（ALS）；运动障碍，包括帕金森氏症；以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.558824,"avgChangeRate":0.039728},{"month":2,"riseRate":0.411765,"avgChangeRate":-0.004843},{"month":3,"riseRate":0.5,"avgChangeRate":-0.022551},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.018344},{"month":5,"riseRate":0.606061,"avgChangeRate":0.032222},{"month":6,"riseRate":0.484848,"avgChangeRate":0.01808},{"month":7,"riseRate":0.666667,"avgChangeRate":0.035186},{"month":8,"riseRate":0.575758,"avgChangeRate":0.030603},{"month":9,"riseRate":0.484848,"avgChangeRate":0.022099},{"month":10,"riseRate":0.529412,"avgChangeRate":0.057649},{"month":11,"riseRate":0.588235,"avgChangeRate":0.013418},{"month":12,"riseRate":0.470588,"avgChangeRate":0.036176}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}